PremiumThe FlyHookipa Pharma downgraded to Sector Perform from Outperform at RBC Capital Hookipa Pharma price target lowered to $7 from $24 at JMP Securities Hookipa Pharma announces workforce reduction of 80%, pause of eseba-vec program PremiumThe FlyJMP Securities healthcare analysts hold an analyst/industry conference call Is HOOK a Buy, Before Earnings? Hookipa Pharma doses first patients with eseba-vec PremiumThe FlyHookipa Pharma price target raised to $24 from $23 at JMP Securities Hookipa Pharma reports Q2 EPS ($1.52), consensus ($1.25) Hookipa Pharma Announces Executive Reshuffle and Board Enhancements 
